We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
+76.9%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$143M
Cap. Flow
+$59.6M
Cap. Flow %
13.05%
Top 10 Hldgs %
62.11%
Holding
49
New
15
Increased
14
Reduced
8
Closed
4

Top Buys

1
CELC icon
Celcuity
CELC
+$11.1M
2
TNGX icon
Tango Therapeutics
TNGX
+$9.52M
3
PALI icon
Palisade Bio
PALI
+$9.23M
4
TERN
Terns Pharmaceuticals
TERN
+$8.67M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$8.65M

Top Sells

1
QURE icon
uniQure
QURE
+$19.7M
2
MRUS
Merus
MRUS
+$11.3M
3
NKTR icon
Nektar Therapeutics
NKTR
+$7.11M
4
CYTK icon
Cytokinetics
CYTK
+$6.22M
5
DNLI icon
Denali Therapeutics
DNLI
+$3.63M

Sector Composition

1 Healthcare 99.72%
2 Consumer Staples 0.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
1
Tango Therapeutics
TNGX
$4.5B
$96.4M 21.09%
10,876,219
+1,104,734
+11% +$9.52M
RVMD icon
2
Revolution Medicines
RVMD
$38.1B
$31.9M 6.97%
400,000
– –
KOD icon
3
Kodiak Sciences
KOD
$2.58B
$31.8M 6.95%
1,136,000
+386,000
+51% +$7.9M
KYMR icon
4
Kymera Therapeutics
KYMR
$9.38B
$25.6M 5.6%
329,100
+10,000
+3% +$675K
CELC icon
5
Celcuity
CELC
$4.31B
$22.4M 4.91%
225,000
+135,000
+150% +$11.1M
ABVX
6
Abivax
ABVX
$12B
$16.9M 3.69%
125,000
+5,000
+4% +$546K
PTCT icon
7
PTC Therapeutics
PTCT
$6.51B
$15.2M 3.33%
200,000
– –
TERN
8
DELISTED
Terns Pharmaceuticals
TERN
$15.2M 3.32%
+375,000
New +$8.67M
PTGX icon
9
Protagonist Therapeutics
PTGX
$8.49B
$14.8M 3.25%
170,000
+60,000
+55% +$4.91M
PRAX icon
10
Praxis Precision Medicines
PRAX
$8.59B
$13.7M 3%
+46,457
New +$8.65M
URGN icon
11
UroGen Pharma
URGN
$1.95B
$11.7M 2.56%
500,000
-75,000
-13% -$1.63M
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$11.7M 2.56%
53,000
+5,000
+10% +$808K
PALI icon
13
Palisade Bio
PALI
$328M
$11.3M 2.47%
+4,799,875
New +$9.23M
AMLX icon
14
Amylyx Pharmaceuticals
AMLX
$1.89B
$9.66M 2.12%
800,000
-100,000
-11% -$1.36M
SRZN icon
15
Surrozen
SRZN
$241M
$9.4M 2.06%
+416,150
New +$6.73M
CAPR icon
16
Capricor Therapeutics
CAPR
$1.11B
$9.38M 2.05%
+325,000
New +$4.24M
DFTX
17
Definium Therapeutics
DFTX
$5.85B
$8.01M 1.75%
598,500
+435,000
+266% +$5.38M
COGT icon
18
Cogent Biosciences
COGT
$6.48B
$7.99M 1.75%
+225,000
New +$6.33M
REPL icon
19
Replimune Group
REPL
$799M
$7.29M 1.6%
750,000
-300,000
-29% -$2.55M
QURE icon
20
uniQure
QURE
$2.71B
$6.94M 1.52%
290,000
-510,000
-64% -$19.7M
CYTK icon
21
Cytokinetics
CYTK
$10.9B
$6.35M 1.39%
100,000
-100,000
-50% -$6.22M
HELP
22
Cybin Inc
HELP
$436M
$5.85M 1.28%
+715,000
New +$4.6M
PGEN icon
23
Precigen
PGEN
$1.76B
$5.75M 1.26%
1,375,000
+525,000
+62% +$2.03M
CTNM
24
Contineum Therapeutics
CTNM
$524M
$5.65M 1.24%
+494,000
New +$5.64M
CBIO
25
Crescent Biopharma
CBIO
$417M
$5.38M 1.18%
453,686
– –
1
2

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
FTF
Freedom Together Foundation New York $762M AUM 15.13% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
PMWMG
Parr McKnight Wealth Management Group Minneapolis, Minnesota $763M AUM 13.49% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $763M AUM 30.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Boxer Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, Boxer Capital Management held 49 positions worth $457M, up 46% from $314M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Boxer Capital Management deployed $59.6M of net new capital in Q4 2025, opening 15 new positions and adding to 14 existing holdings. Its largest new stake was Palisade Bio: 4,799,875 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was uniQure, an estimated $19.7M trimmed.

  • Boxer Capital Management's largest Q4 2025 buy was Palisade Bio: 4,799,875 shares worth $11.3M.
  • Boxer Capital Management added most to Celcuity in Q4 2025, an estimated $11.1M increase.
  • Boxer Capital Management's biggest Q4 2025 reduction was uniQure, cutting an estimated $19.7M.
  • Boxer Capital Management fully exited Merus in Q4 2025, selling an estimated $11.3M.
  • Boxer Capital Management's ten largest holdings make up 62% of its $457M portfolio in Q4 2025.
  • Boxer Capital Management opened 15 new positions and closed 4 in Q4 2025.
  • Boxer Capital Management's portfolio value rose 46% quarter-over-quarter to $457M.

Based on Boxer Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.